Flexible Initial Dosing of Atorvastatin Based Upon Initial Low-Density Lipoprotein Cholesterol Levels in Type 2 Diabetic Patients

Atorvastatin Study Group in Korea

Background/Aims: We used flexible starting doses and early titration of atorvastatin to determine the rate of achievement of a low-density lipoprotein cholesterol (LDL-C) target for hyperlipidemic patients with type 2 diabetes mellitus.

Methods: This study was a multicenter, open-label, prospective trial of atorvastatin therapy in hyperlipidemic patients with type 2 diabetes. The patients were divided into three groups according to initial LDL-C levels (130-149, 150-159 and ≥160 mg/dL), and 10, 20, and 40 mg of atorvastatin was administered to each group, respectively. If LDL-C did not reach the 100 mg/dL target level at four weeks after initiation of treatment, the doses were increased by one step. Endothelial function tests and plasminogen activator inhibitor (PAI)-1 levels were measured in 41 patients.

Results: Groups of 62, 18, and 69 patients were started on 10, 20, and 40 mg of atorvastatin, respectively, and 91% of the patients achieved the LDL-C target after four weeks of treatment. The overall percentage of patients achieving the LDL-C target after eight weeks of treatment was 89.3%: 87.5% in the 10 mg group, 86.4% in the 20 mg group, 93.9% in the 40 mg group, and 66.7% in the 80 mg group. A statistically significant reduction was observed in the mean percentage change in flow-mediated endothelium-dependent dilatation after eight weeks of treatment (p<0.0001).

Conclusions: Flexible initial dosing and early aggressive titration of atorvastatin according to LDL-C levels is an efficient and safe strategy for achieving the target level and for improving endothelial dysfunction in hyperlipidemic patients with type 2 diabetes.

Key Words: Atorvastatin; Low-density lipoprotein cholesterol (LDL-C); Type 2 diabetes mellitus; Flow-mediated endothelium-dependent dilatation (FMD); Flow-mediated endothelium-independent dilatation (EID)

INTRODUCTION

The development of type 2 diabetes mellitus (T2DM) is accompanied by multiple risk factors for developing coronary heart disease (CHD), such as hypertension, obesity, and dyslipidemia. Among modifiable risk factors, the association between plasma low-density lipoprotein cholesterol (LDL-C) and CHD risk is well established, and this association holds true for individuals with diabetes even at low plasma LDL-C concentrations. Based on several large-scale randomized controlled trials, the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), stated that diabetes is a coronary heart disease equivalent. Thereafter, the American Diabetes Association (ADA) recommended more aggressive pharmacological therapy in the management of dyslipidemia for adults with diabetes. The LDL goal was set at <100 mg/dL. The ADA recommended that drug therapy should be initiated at the same time as lifestyle intervention is started if the LDL-C level is 130 mg/dL or greater in the absence of coronary, peripheral, and cerebral vascular diseases, whereas it should be initiated at an LDL-C level of 100
mg/dL or greater in their presence[9]. However, among patients treated with statins, the rate of achieving a reduced LDL-C goal after 16 weeks of treatment was 65% with the usual dose of atorvastatin, but only 19% with pravastatin[6, 10]. This suggests that a more practical and aggressive strategy for rapidly and effectively reaching a given treatment goal of reduced LDL-C levels is urgently needed for patients with diabetes.

So far, there has been no 'gold standard' for the starting dose and dose titration of a statin according to a patient’s LDL-C levels, toward the end of achieving the target level. If patients were started on a dose of a statin by anticipating its effect instead of relying on dose escalation, then the reduced LDL-C target might be reached more rapidly and effectively. Furthermore, appropriate dose adjustment of the statin based on LDL-C levels may also be essential for achieving the goal. The cholesterol-lowering effect of atorvastatin usually reaches its maximum level at four weeks, with subsequent maintenance of a similar effect throughout the period of therapy[11]. However, there are no clearly established guidelines for the early aggressive titration of statin doses.

Besides the traditional risk factors for coronary heart disease, nontraditional risk factors such as insulin resistance, endothelial dysfunction, impaired fibrinolysis evidenced by elevated levels of plasminogen activator inhibitor type 1 (PAI-1), low-grade inflammation (hs-CRP elevation), microalbuminuria, and vascular wall abnormalities are considered to be contributors to the excess risk of CHD associated with diabetes, which cannot be fully explained in the context of the traditional risk factors alone[12]. Statins also provide beneficial effects for the nontraditional risk factors of CHD. These benefits include restoration of endothelial function, stabilization of atherosclerotic plaques, and decreases in oxidative stress and vascular inflammation. In addition to its lipid-lowering effect, atorvastatin has also shown an anti-inflammatory effect associated with improved endothelial-dependent dilation in a prospective study[13, 14].

In this study, we first tested the effects of initial flexible doses and early aggressive dose titration of atorvastatin according to the patient’s LDL-C levels as a practical guideline for statin therapy. Second, we measured the non-lipid-lowering effects of atorvastatin in the same patients, based on flow-mediated endothelium-dependent dilation (FMD), flow-mediated endothelium-independent dilation (EID), and PAI-1 levels.

**MATERIALS AND METHODS**

**Patients**

Men and women aged 18-80 years were eligible for the study if they were hyperlipidemic T2DM patients with LDL-C levels ≥ 130 mg/dL or glycated hemoglobin (HbA1c) values of ≤ 10% and triglyceride levels of ≤ 400 mg/dL at baseline. Patients were not included in this study if they had type 1 diabetes mellitus or serious medical illness, or if they had been treated with fibrates, corticosteroids, azole-derivative antifungal agents, or niacin. Patients were also excluded if they were women of childbearing potential not using contraception, or if they had secondary causes of hyperlipoproteinemia (thyroid-stimulating hormone ≥ 1.5 times the upper limit of normal, blood urea nitrogen ≥ 30 mg/dL, or creatinine ≥ 2.0 mg/dL at baseline), uncontrolled hypertension (sitting systolic blood pressure [BP] ≥ 160 mmHg, sitting diastolic BP ≥ 100 mmHg), hepatic disease, or impaired hepatic function (aspartate or alanine aminotransferase [AST/ALT] levels > two times the upper limits of normal at baseline). Other exclusion criteria were: creatine phosphokinase (CPK) ≥ three times the upper limit of the normal range at baseline, body mass index (BMI) ≥ 32 kg/m², a history of intolerance or hypersensitivity to HMG-CoA reductase inhibitors, or abuse of alcohol or other recreational drugs. Patients with cardiac arrhythmia were not included in the group receiving endothelial function measurements.

**Study design**

This multicenter, open-labeled, prospective study was conducted at 11 university-affiliated diabetes centers in Korea. Patients received appropriate doses of atorvastatin according to designed criteria for a total of eight weeks. Patients who were on any other lipid-lowering medications before enrollment underwent a four-week washout period before being placed on the standard protocol. The patients were divided into three groups according to their initial LDL-C levels (130-149 mg/dL, 150-159 mg/dL, and ≥ 160 mg/dL), and 10, 20, and 40 mg of atorvastatin was administered as an initial dose in each group, respectively.

If the patient’s LDL-C levels did not reduce to the target level after four weeks of treatment, the dose was increased by one step, up to 80 mg. If the LDL-C levels met the target after four weeks of treatment, the dose was maintained at the same level. All the patients were encouraged to adhere to their allocated diet or exercise therapy during the entire study period. The study was conducted according to the principles of the Declaration of Helsinki; it was approved by institutional review boards at all centers, and written informed consent was obtained from all patients.

**Determination of sample size**

The sample size was determined to be adequate to address the study hypothesis that atorvastatin treatment would enable patients to achieve their designated LDL-C target quickly, with either no titration or just one titration step, provided the starting dose was appropriate for the level of LDL-C reduction required.
by the patient’s cardiovascular risk category, 151 patients were needed to make the study adhere to our assumed percentages: 50% of patients reaching goal, 20% dropouts, and a lower bound of a one-sided 95% confidence interval with a width of 15% of the target population. However, we determined the final sample size of 198 patients to secure adequate patients.

Assessments

Fasting serum lipid profiles in all centers, and endothelial function and PAI-1 level measurements in three centers, were assessed for efficacy. Patients were instructed to fast for 12 h before each test, and they had no vigorous exercise or change in diet the day before the test. Total cholesterol (TC) and triglyceride (TG) levels were measured enzymatically after precipitation of the other lipoproteins. The LDL-C level was calculated using Friedewald’s equation if the serum triglyceride level was ≤400 mg/dL. The blood glucose level was measured using an automatic enzymatic method, and the glycated hemoglobin (HbA1c) level was determined by high-performance liquid chromatography (HPLC; Variant II HbA1c analyzer; Bio-Rad, Montreal, Quebec, Canada) with a reference range of 4.4~6.4% of total hemoglobin.

Endothelial function was assessed at baseline and at week eight by echocardiography with monitoring of electrocardiograms, which measured brachial artery flow-mediated endothelial-dependent dilation (FMD) and brachial artery flow-mediated endothelium-independent dilation (EID). Echocardiography was performed in three of the centers, and the measurements of FMD and EID by recorded images were performed by one investigator. PAI-1 levels were measured using enzyme-linked immunosorbent (ELISA) kits (Biopool, Umea, Sweden) at baseline and at week eight. Physical examinations, measurements of blood pressure and body weight, and laboratory tests were performed at each visit, and any adverse event (AE) was recorded for safety evaluation.

Outcome measures

The primary efficacy variable was the percentage of patients achieving their National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Adult Treatment Panel III (NCEP ATP III) target of LDL-C<100 mg/dL at eight weeks. The secondary efficacy variables included the percentage changes, from baseline to eight weeks, of LDL-C, HDL-C, triglycerides, total cholesterol, non-HDL cholesterol, (LDL cholesterol)/(HDL cholesterol) ratio, PAI-1, FMD, and EID.

Statistical analysis

All patients in the per protocol (PP) population were analyzed for efficacy. The PP population consisted of patients who were assigned to a starting dose of atorvastatin, who had both baseline and eight-week LDL cholesterol efficacy measurements, and who adhered to the protocol requirements. For safety analysis, patients who had at least one medication were included, and the last-observation-carried-forward (LOCF) approach was used to evaluate missing data,

Descriptive statistics such as mean, standard deviation, frequency, and percentage have been used to present the distributions of baseline characteristics, efficacy, and safety measurements. The primary efficacy variable was the percentage of patients achieving their LDL-C NCEP ATP III target at eight weeks. The overall rate of achieving the target LDL-C 95% confidence intervals (CI) are presented. The Chi-square test was used to compare the difference of rates among starting doses of atorvastatin. The baseline characteristics of the two outcome groups (success or failure to achieve the target) were compared using Satterthwaite or Student’s t-tests,

The secondary efficacy variables were the percentage changes from baseline to eight weeks in the following lipid parameters: LDL cholesterol, HDL cholesterol, TG, TC, non-HDL cholesterol, (LDL cholesterol)/(HDL cholesterol) ratio, FMD, and EID: and the percent change from baseline to eight weeks in the PAI-1 level. Mean percentage changes from baseline in lipid parameters and PAI-1 were compared using paired t-tests.

We used SAS version 8.01 for statistical analysis; all tests were two-sided with significance assumed at p<0.05.

RESULTS

Patient population

Of 322 subjects screened, evaluable safety data were available for 209 patients. Among them, 149 patients completed this study, and all the analyzed data for the efficacy are based on this group (Figure 1). The mean age was 58.4±8.5 y (range 32-76 y), and 106 (71.1%) of the patients were women (Table 1). According to the initial LDL-C levels, 62 (41.6%), 18 (12.1%), and 69 (46.3%) of the 149 patients were assigned to receive 10, 20, and 40 mg doses of atorvastatin, respectively.

Efficacy

After the first assessment at week four, 9.7% of patients in the 10 mg group, 11.1% of patients in the 20 mg group, and 8.7% of patients in the 40 mg group were changed to higher doses. Thus, 56 (37.6%), 22 (14.8%), 65 (43.6%) and 6 (4%) of the 149 patients received 10, 20, 40, and 80 mg of atorvastatin, respectively, starting at this point (Figure 2, 3).

At the end of the study in all dose groups, 89% of all patients achieved the target LDL-C level (95% CI, 84%~94%). The target was achieved by 66.7% of patients in the 80 mg group, 93.9%
Table 1. Baseline characteristics of subjects (n=149)

| Characteristic               | Mean±SD         |
|------------------------------|-----------------|
| Men / Women                  | 43 (28.9%) / 106 (71.1%) |
| Age (yrs)                    | 58.4±8.5        |
| Body mass index (kg/m²)      | 24.8±2.7        |
| Diabetic duration (yrs)      | 7.9±7.0         |
| HbA1c (%)                    | 7.5±1.1         |
| Fasting blood glucose (mg/dL)| 147.8±42.7      |
| History of antihyperlipidemic agents (Yes / No) | 15 (10.1%) / 134 (89.9%) |
| Height (cm)                  | 159.4±8.0       |
| Weight (kg)                  | 63.3±9.2        |
| LDL-C level (mg/dL)          | 160.3±22.4      |

Table 2. Percentage of patients achieving NCEP-LDL cholesterol goal at week 8 (n=149)

| Group | Number (achieved/total) | Achieving Rate † |
|-------|--------------------------|------------------|
| 10 mg | 49 / 56                  | 87.5%            |
| 20 mg | 19 / 22                  | 86.4%            |
| 40 mg | 61 / 65                  | 93.9%            |
| 80 mg | 4 / 6                    | 66.7%            |
| Total | 149                      | 89.3%            |

†Chi-square test p=0.1722 (95% confidence interval 84.3~94.2)

in the 40 mg group, 86.4% in the 20 mg group, and 87.5% in the 10 mg group (Table 2).

Serum parameters from baseline to eight weeks were significantly lowered for LDL-C (-51.2±15.6%), TC (-39.0±11.9%), TG (-21.6±42.0%), and non-HDL-C (-47.1±13.6%) (Figure 4). Among the lipid parameters, LDL-C, TC, and non-HDL-C values were significantly decreased after eight weeks compared with baseline levels, in a dose-dependent manner (p<0.0001). Atorvastatin was more effective in lowering TG in the 20 mg group and inducing greater change in LDL-C/HDL-C ratio in the 40 mg group than the other groups, but there were no statistically significant differences among groups, respectively (p=0.2128, p=0.9875). Interestingly, the HDL-C level of the 40 mg group was significantly lowered compared with the 10 mg and 20 mg groups (p=0.0079).
Table 3. Characteristics of each covariate in success or failure group (N=149)

| Characteristic       | Success (N=133) | Failure (N=16) | Satterthwaite or t-test |
|----------------------|-----------------|---------------|------------------------|
| Age (yrs)            | 58.5±8.5        | 58.1±8.8      | p=0.8833               |
| BMI (kg/m²)          | 24.9±2.7        | 24.5±2.5      | p=0.5414               |
| Diabetic duration (yrs) | 8.2±7.2       | 5.6±4.0       | p=0.0333*              |
| LDL-C (mg/dL)        | 160.3±21.8     | 160.1±27.2   | p=0.9791               |
| Baseline             | 71.3±14.9       | 123.0±22.9   | P(0.0001)              |
| End point (8 week)   | 10.8±18.4       | 123.0±22.9   | p=0.5320               |
| Insulin (IU/mL)      | 7.7±8.0        | 123.0±22.9   |                        |
| Hemoglobin A1c (%)   | 7.6±1.2        | 7.2±1.0      | p=0.2401               |

Subgroup analysis (success vs. failure groups)

The rates of patients achieving their target did not show any significant differences in relation to covariates (Table 3). Of the 149 total patients, 135 (90.6%) reached the target level of LDL-C at four weeks, but 12 (8%) of these patients had elevated LDL-C levels (>100 mg/dL) at eight weeks. Fourteen patients needed to increase their dosage at four weeks because they did not reach the target at four weeks (‘failure’). The success and failure groups did not differ significantly in age, BMI, baseline LDL-C insulin, or HbA1c levels, but did show differences in the duration of diabetes (success vs. failure, 8.2±7.2 vs. 5.6±4.0 years, p(0.05) (Table 3).

Endothelial function measurements

The baseline clinical characteristics of the endothelial function study subpopulation are listed in Table 4. Atorvastatin supplementation improved FMD after eight weeks of treatment (Figure 5), but EID was not significantly affected. PAI-1 tended to decrease in patients receiving atorvastatin, but this parameter change did not reach statistical significance.

Safety

Among the 209 original study subjects, 30 patients treated with atorvastatin reported 41 adverse events. Of these, 24
### Table 4. Pre- and post-treatment values and percentage changes of FMD, EID, and PAI-1

|                          | Week 0       | Week 8       | % change                  | p value  |
|--------------------------|--------------|--------------|----------------------------|----------|
| FMD (%)                  | 8.3±4.0      | 11.0±4.1     | 46.4±52.0**               | 0.0001   |
|                          | (1.4~17.9)   | (1.8~21.1)   | (-23.0~200)               |          |
| EID (%)                  | 15.5±5.4     | 15.9±5.2     | 4.3±14.7                  | 0.0714   |
|                          | (5.7~28.9)   | (6.1~28.1)   | (-36.9~36.0)              |          |
| PAI-1 (IU/mL)            | 27.1±10.2    | 25.1±12.2    | -0.2±46.0                 | 0.9733   |
|                          | (9.8~51.6)   | (4.6~52.0)   | (-78.5~113.1)             |          |

Data are means±SD (range). FMD, flow-mediated endothelium-dependent dilation; EID, flow-mediated endothelium-independent dilation; PAI-1, plasminogen activator inhibitor-1.

### Table 5. Summary of safety analysis

|                                | Number (%) |
|--------------------------------|------------|
| Subjects analyzed for safety   | 209 (100)  |
| Subjects with adverse events   | 30 (14.4)  |
| Subjects with drug-related adverse events | 24 (11.5)  |
| Subjects withdrawn due to drug-related adverse events | 7 (3.3)    |
| Subjects withdrawn due to drug-related laboratory adverse events | 3 (1.4)    |
| Case of adverse events (> 1%)  |            |
| Abdominal pain                 | 6          |
| ALT increase                   | 5          |
| Dizziness                      | 4          |
| Headache/ Dyspepsia            | 3          |
| Creatine phosphokinase increase| 3          |

1) Erythematous rash, pruritus, rash, abdominal pain, dizziness, dyspnea  
2) AST/ALT increase, abnormal urine analysis, phosphatase alkaline increase, creatine phosphokinase increase

DISCUSSION

In this study, we aimed to develop an intensive treatment guideline for lipid-lowering therapy that would achieve an LDL-C target in T2DM patients rapidly and effectively. We therefore observed the rate of achieving the NCEP treatment goal within eight weeks of atorvastatin therapy, with the starting dose stratified according to the individual patient’s baseline LDL-C level. Atorvastatin, administered at 10, 20, 40, and 80 mg, produced effective reductions in total cholesterol and LDL-C within eight weeks.

Many primary and secondary prevention studies provide strong support for the use of moderate doses of statins in patients with diabetes. Although the NCEP and ADA guideline for the LDL-C target is 100 mg/dL, only a few studies support the idea that lower LDL-C levels lead to better cardiovascular outcome. The Heart Protection Study (HPS), which had the largest diabetes subgroup, demonstrated a consistent (close to 25%) reduction and a 5-7% absolute risk reduction in cardiovascular events with statin therapy regardless of initial LDL-C levelseven among patients whose initial levels were below the NCEP target of 100 mg/dL. For better cardiovascular outcome, aggressive therapy with statins is warranted in diabetic subjects. However, the effectiveness of the available statin
medications in lowering LDL-C is variable. Most statins are capable of achieving the LDL-C goal in subjects with LDL-C levels of less than 170 mg/dL. Atorvastatin at 40 mg or simvastatin at 80 mg could achieve the goal in subjects with LDL-C levels of 170-189 mg/dL, but only atorvastatin at 80 mg and the recently developed drug rosuvastatin could do so for subjects with LDL-C levels ≥190 mg/dL. To achieve the desired target of 100 mg/dL, dose adjustment would inevitably be needed in subjects with higher LDL-C levels. Considering the time and cost efficacy, starting-dose stratification seemed to be a valuable method in daily clinical practice and was eventually revealed to be so in this study, as shown by the LDL-C target achievement rate of 89% at eight weeks. Furthermore, most of the LDL-C reduction was achieved within four weeks. The clinical characteristics of subjects who achieved the target level were not different from those of who did not achieve it, except for the overall duration of diabetes mellitus. However, because most patients achieved the target level, the ‘failure’ group was small. If more subjects had been studied, differences between the success and failure groups might have been more clearly defined.

The mean percentages of LDL-C, total cholesterol, and non-HDL cholesterol were all reduced in a dose-dependent manner from baseline. The mean LDL-C changes were higher than the CURVES study achieved with initial dose randomization. Initial dose stratification could explain the differences in the effectiveness of the same dosage of the same drug. Moreover, the HDL cholesterol level was slightly increased in the 10 mg and 20 mg groups, and decreased in the 40 mg group, after eight weeks of treatment. The degree of TG decrease was also smaller in the 40 mg group than in the 20 mg group, although this was not statistically significant.

Endothelial dysfunction occurs early in the atherosclerotic process and is associated with other cardiovascular risk factors. Impairment of fibrinolytic activity has been reported in dysmetabolic conditions associated with atherosclerosis, such as diabetes mellitus, and is related to endothelial function. Recent studies have suggested that statins might have pleiotropic effects on endothelial function beyond their lipid-lowering effect. Several mechanisms by which statins might improve endothelial function, including increasing the synthesis of nitric oxide, decreasing the synthesis of endothelin-1, and inhibiting LDL-cholesterol oxidation, have been suggested. We showed that treatment with atorvastatin for eight weeks significantly improved endothelial function in patients with type 2 diabetes. Atorvastatin also reduced the PAI-1 levels, but the effect failed to reach statistical significance, probably because the study was short and patients showed considerable variation in their PAI-1 levels. Although further studies are needed to elucidate the mechanisms, these results suggest that early treatment with atorvastatin could reduce the incidence of coronary heart disease in patients with diabetes.

A few adverse events were reported in this study. Ten patients withdrew because of drug-related events. Among them, three showed drug-related adverse biochemical changes (elevations in ALT or CPK levels), which were reversible after drug discontinuation. Thus, atorvastatin appears to be relatively safe for the treatment of patients with T2DM, even at high doses.

In conclusion, an initial flexible dose of atorvastatin treatment based on initial LDL-C levels can achieve a target LDL-C level effectively, rapidly, and safely in most hyperlipidemic patients with T2DM. Therefore, this dose-escalation schedule might be helpful, especially for high-risk patients seen in daily clinical practice. However, the clinical significance remains to be clarified by future studies.

Appendix

Participants of the Atorvastatin Study Group in Korea are as follows: H.Y., Son, K.H., Yoon, Y.H., Choi, H.S., Kwon, S.H., Ko, Department of Internal Medicine; The Catholic University of Korea: I.K., Lee, H.S., Kim, K.K., Park, M.J., Kim, Department of Internal Medicine; The Keimyung University, School of Medicine; J.T., Woo, Y.S., Kim, Department of Internal Medicine, Kyung Hee University College of Medicine; D.S., Choi, Department of Internal Medicine, Korea University College of Medicine; M., K., Lee, H.J., Kim, Department of Internal Medicine, SungKyunKwan University School of Medicine; K., S., Park, H., K. Lee, Seoul National University College of Medicine; J., Y., Park, E. H., Koh, University of Ulsan College of Medicine; H. C., Lee, B. S., Cha, Yonsei University College of Medicine; M., Y., Chung, D. H., Cho, Chonnam National University College of Medicine; Y. K., Kim, I. J., Kim, Pusan National University College of Medicine; Y. K., Kim, B. J., Ku, Chungnam National University College of Medicine.

REFERENCES

1) Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 104:25-35, 1998

2) Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 76:69C-77C, 1995

3) Goldberg RB, Mellies MJ, Sacks FM, Moyer LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Circulation 98:2513-2519, 1998

4) Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005-2016, 2003
5) Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
6) Wiklund O, Haversen L, Pettersson C, Hulten LM. How can we prevent cardiovascular disease in diabetes. J Intern Med 262:199-207, 2007
7) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult treatment panel III). JAMA 285:2486-2497, 2001
8) Haffner SM. Dyslipidemia management in adults with diabetes. Diabetes Care 27(Suppl 1):S68-S71, 2004
9) Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 130:191-197, 1997
10) Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) vs simvastatin (10mg) at six weeks. Am J Cardiol 87:554-549, 2001
11) Heinonen TM, Stein E, Weiss SR, McKinney JM, Davidson M, Shurzinska L, Black DM. The lipid-lowering effects of atorvastatin; a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 18:853-863, 1996
12) Fonseca V, Descouza C, Asnani S, Jalal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25:153-175, 2004
13) Marchesi S, Lupattelli G, Siepi D, Schiacci G, Vaudo G, Rosini AP, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36:617-621, 2000
14) Guerci B, Bohme P, Kearney-Schwartz A, Zarrad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Diabetes Metab 27:436-447, 2001
15) Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
16) Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia. Clin Ther 26:1388-1399, 2004
17) Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587, 1998
18) Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasodilatation induced by acetycholine in atherosclerotic coronary arteries, N Engl J Med 315:1046-1051, 1986
19) Gough SC, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med 8:988-995, 1991
20) Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657, 2000
21) Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pasquala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J Clin Invest 101:2711-2719, 1998
22) van den Akker JM, Breedie SJ, Diepenveen SH, van Tits LJ, Stakenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL, J Nephrol 16:238-244, 2003